PATENT CLAIM ANALYSIS

Application Number: 15746828
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "300000"]

Abstract:
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

Claim (Index 4):
4-[1-[[4-[3,4-Difluorophenyl)methyl]-2,3-dihydropyrido[4,3-b][1,4]oxazin-5-yl]amino]cyclopropyl]benzoic acid or a salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 86.0
- Lexical Diversity: 1.55932
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15534855', '15820429', '14779347', '13853394', '16083295']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7507329930118926
- 35 USC 102 Novelty (BERT): 0.4984835174739847
- Combined Prediction Score: 0.7255080454581018
- Mean Citation Score: 253.09679000000008
- Max Citation Score: 260.92844
- Similarity Product: 229.92502859614848

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test